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Myocardial Scarring in Cardiac Sarcoidosis
What to Learn From a Systematic Review and Meta-Analysis?*Albert de Roos, MD,a Annette van den Berg-Huysmans, MSC,a Jan W. Schoones, MAbC ardiac sarcoidosis can present as part of mul-tiorgan involvement or increasingly as anisolated or subclinical heart manifestation.
Late gadolinium enhancement (LGE) by cardiac mag-
netic resonance (CMR) has prognostic value by
detecting cardiac involvement in sarcoidosis (1).
However, there is no consensus in the literature on
the prognostic implications of LGE-CMR in this clini-
cally relevant setting. This lack of consensus due to
multiple small and single-centered studies motivated
Coleman et al. (2) to perform a systematic review and
meta-analysis on the prognostic value of CMR in pa-
tients with known or suspected cardiac sarcoidosis,
as reported in this issue of iJACC. The main conclu-
sion from this study is that the presence of LGE-
CMR in patients with known or suspected cardiac
sarcoidosis is associated with increased odds of both
all-cause mortality and arrhythmogenic events.SEE PAGE 411What can we learn from a systematic review and
meta-analysis? Pooling the data from multiple studies
may provide a more precise estimate of the prog-
nostic implications of a positive LGE-CMR test in
patients with known or suspected cardiac sarcoidosis.
However, McInnes and Bossuyt (3) describe a number
of common pitfalls of systematic reviews and meta-
analyses in imaging research. The study by Coleman
et al. (2) complies to most of the recommended
guidelines (e.g., PRISMA [Preferred Reporting Items*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the aDepartment of Radiology, Leiden University Medical Center,
Leiden, the Netherlands; and the bWalaeus Library, Leiden University
Medical Center, Leiden, the Netherlands. The authors have reported
that they have no relationships relevant to the contents of this paper to
disclose.for Systematic Reviews and Meta-Analyses] state-
ment) and avoids a number of pitfalls as described by
McInnes and Bossuyt (3). Journals are increasingly
requesting authors to adhere to guidelines such as the
PRISMA statement to verify the completeness of the
systematic review and analysis (4).
The current study addresses a well-defined clinical
question and provides more precise estimates of the
prognostic implications of CMR in cardiac sarcoidosis.
However, the literature search of this systematic re-
view and meta-analysis has 2 weaknesses. First, the
selection of databases could be improved. The au-
thors consulted only 3 databases (PubMed, PubMed
Central, and the metaRegister of Controlled Trials).
Two databases of considerable value were not used
(Embase, Web of Science) and several databases of
additional value were not used as well (e.g., CINAHL,
Academic Search Premier, ScienceDirect).
Second, the search strategy used is not fully
shown. The formulation of the search strategy as is
shown in the article is unclear. As such, it is not
possible to exactly reproduce the search. According to
the authors, 519 references were found, but it is not
known what the numbers per database are. Applying
the given strategy in PubMed results in 86 references
(June 9, 2016). If one would compose a search strat-
egy according to McInnes and Bossuyt (3), the num-
ber of retrieved references in PubMed is 496 (June 9,
2016). Furthermore, applying this strategy in, for
example, Embase, would to a set of 1,350 references,
of which 929 references are unique compared to the
references identified in PubMed (excluding 521
meeting abstract references). The consultation of
additional databases next to Embase will add more
references as well. These 2 weaknesses call out for the
expert eye of the medical librarian (5).
The process of selecting studies for systematic re-
view and meta-analysis is complex. It is arguably the
most important aspect in the process of integrating
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422research on a specific topic. The selection process is
important because the inclusion and exclusion of
studies affects the scope and validity of meta-analysis
results. The inclusion and exclusion criteria in this
meta-analysis are clear and the steps taken in the
study selection process are generally well described
and a detailed flow chart was produced.
According to the PRISMA statement the data
collection process should be well described. However,
the methods used for data extraction in the current
study are not entirely clear. It is important to not only
indicate which characteristics were recorded, but
also describe the method that was used to abstract
data. It is unclear if a standardized data abstraction
form was used. Given the importance of systematic
and reproducible data retrieval, it is advisable to use
such a form.
As recommended by McInnes and Bossuyt (3), the
authors determined a quality score for each study
included in the meta-analysis, using the Newcastle-
Ottawa quality assessment scale. As with data
abstraction, 2 reviewers assessed the quality. How-
ever, agreement between reviewers and method of
reconciliation in differences were not reported.
The statistical analysis of the data was well plan-
ned and appropriate techniques were used. The risk
of publication bias was assessed using funnel plots
and Egger’s test. Variation across studies (heteroge-
neity) was also considered, including the exploration
of the sources of this variation, using metaregression
and sensitivity analyses.
A number of limitations inherent to their system-
atic review and meta-analysis were discussed by
Coleman et al. (2). For example, the measurement of
LGE was not standardized throughout the literature
introducing additional heterogeneity of methods.
Binary visual scoring, using different thresholds for
(semi)quantification, the extent of LGE involving the
left or right ventricle, and various patterns of LGE
(e.g., right ventricular involvement, multifocal, sub-
epicardial, intramural, subendocardial, transmural)
may all contribute to heterogeneity.
Coleman et al. (2) also discuss that despite a near
normal left ventricular ejection fraction, patients
with LGE positivity have higher odds of adverse
events (2). It is acknowledged that the assessment of
the interaction between ejection fraction and LGE
was hindered by the lack of patient-level covariates.
The authors suggest that future prospective studies
may help mitigate selection bias and provide patient-
level data. A recent study addressed the increased
risk in cardiac sarcoidosis in patients with LGE and
preserved ejection fraction (6). LGE burden was
quantified by defining myocardial areas with a signalintensity 5 standard deviations above presumed
normal myocardium. The LGE burden and severity of
right ventricular dysfunction even in patients with
preserved left ventricular function were associated
with increased rate of death and ventricular ar-
rhythmias, underscoring again the potential predic-
tive value of LGE extent. In particular, multifocal
right ventricular LGE was associated with the
endpoint of ventricular tachycardia–fibrillation or
death. The presence of a low LGE burden was not
associated with adverse outcomes (6).
A limitation with LGE-CMR assessment of scar tis-
sue is the lack of an established gold standard tech-
nique for accurate quantification. Several different
techniques have been proposed for quantifying acute
and chronic scar, including manual contouring and
thresholding techniques such as a signal intensity
threshold of 2, 3, 5, or 6 standard deviations above the
normal remote myocardium, the Otsu technique, and
the full width at one-half maximum technique.
Myocardial scar quantification by LGE-CMR varies
depending on the quantification method used (7).
Recently, the full width at one-half maximum
method was used in patients with cardiac sarcoidosis
to quantify LGE as a percentage of the left ventricle.
In particular the extent of LGE appeared to be pre-
dictive for serious cardiac events in patients with
cardiac sarcoidosis and to a lesser degree right ven-
tricular function and scarlike thinning of the basal
interventricular septum (8). Ekstrom et al. (8) call for
re-evaluation of the indications for an implantable
cardioverter-defibrillator in sarcoid patients with
normal left ventricular ejection fraction and sub-
stantial LGE burden.
Overall, LGE burden appears to be the most valu-
able risk marker in patients with known or suspected
cardiac sarcoidosis. A critical threshold of LGE burden
has to be defined by using accurate quantification of
myocardial scar for risk assessment and guiding
treatment. Of note, the LGE extent in patients with
cardiac sarcoidosis may be predictive even in those
with preserved left ventricular function. Compre-
hensive assessment of CMR imaging biomarkers (as
evidenced by future prognostic CMR studies) may
improve risk assessment in patients with cardiac
sarcoidosis by integrating a critical cutoff value for
LGE burden, the pattern of LGE, biventricular func-
tion, and basal septal involvement.
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